A multi-center international study published in NEJM found that performing hematopoietic cell transplants shortly after detecting high-risk features in patients with Shwachman-Diamond Syndrome significantly improves survival rates. The study analyzed 847 cases and found that survival appeared to improve when early HCT treatment occurre...
A phase 2 trial found that vitamin C may benefit people with pre-cancer blood disorders by altering inflammatory signaling molecules and reducing adverse events. The study suggests that vitamin C may help regulate inflammatory pathways associated with growth and progression of pre-cancerous blood cells.
A phase 2 clinical trial found that vitamin C supplements reduced the frequency of anemia, pneumonia, and internal bleeding in patients with pre-cancer blood disorders. The study suggests that vitamin C may improve outcomes in these patients, warranting further investigation in a phase 3 trial.
Researchers developed a new treatment for acute myeloid leukemia (AML) by using AcTor, a molecule that inhibits a signalling protein, in combination with ixazomib. The treatment successfully eliminated cancer cells and leukemic stem cells, showing promising results in mice studies.
A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.
Researchers developed a first-in-class therapy targeting MYC, a protein involved in 70% of cancers, by disrupting its relationship with GSPT1. This approach showed strong anti-cancer activity in multiple types of blood cancers, including treatment-resistant models.
Researchers developed a novel parallel-risk framework to optimize precision transplantation for pediatric patients with acute myeloid leukemia. The framework successfully identifies which patients will benefit from stem cell transplantation directly at diagnosis, overcoming diagnostic biases and subjective clinical assessments.
A research team led by Iowa State University's Raquel Espin Palazon identified two essential components — a pervasive protein and a crucial cellular signaling pathway — needed to make some types of blood cells. Adding these components to leukemia cells could potentially lead to new treatment options.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
Researchers discovered a new epigenetic therapy that remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance. The therapy, NTX-301, consistently reduced leukemia cell survival more effectively than existing hypom...
Acute myeloid leukemia (AML) is classified into 16 subgroups based on its epigenomic features, each with unique clinical prognosis and drug sensitivity. Epigenomic analysis reveals an additional dimension of AML diversity beyond gene mutations alone.
Acute myeloid leukemia transforms lung tissue into an inflammatory environment that promotes tumor cell expansion and impairs respiratory function. Researchers identified galectin-9 and the IL-33/IL1RL1 axis as potential targets for reducing this serious complication.
Researchers at UT MD Anderson Cancer Center have achieved high response rates in patients with hard-to-treat acute myeloid leukemia (AML) using an all-oral combination therapy. The study also provides insights into the origins of cancer, revealing that tumors evolve rapidly through bursts of genetic changes.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
A comprehensive long-term study has demonstrated the efficacy of molecular blood tests in influencing leukemia course. The study found that early intervention based on molecular markers can have a significant impact on disease progression.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
Researchers created a CRISPR-based tool to pinpoint genes the cancer turns off, restoring a key cancer-fighting gene in leukemia. The study found that blocking KDM4 enzymes can regain expression of the tumor-suppressor gene ZBTB7A, reducing leukemia burden while leaving normal blood formation largely unaffected.
The University of Colorado Anschutz Gates Institute has achieved first-in-U.S. FDA clearance for a novel CAR T-cell therapy targeting aggressive leukemia cells, representing a potential new treatment approach for patients with hard-to-treat disease. The therapy will be evaluated in a Phase 1 clinical trial starting this summer.
A new study introduces CoPISA, a high-throughput proteomics workflow that uncovers how drug combinations reshape the soluble proteome. The research team applied CoPISA to two AML drug combinations, revealing conjunctional targeting and vulnerabilities in critical proteins.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers from Dresden University Medicine developed a new treatment approach for relapsed acute myeloid leukemia (AML), combining standard therapy with the BCL2 inhibitor venetoclax. The innovative combination therapy has shown promising efficacy, increasing remission rates to 75% and improving patients' chances of recovery.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Researchers at OHSU discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome treatment resistance by pairing venetoclax, a standard AML drug, with palbociclib, a cell-cycle inhibitor approved for breast cancer. The study found that this combination produced significantly stronger and m...
A new study by University of Maryland researchers found that Black patients with aggressive leukemia have lower survival rates and are more likely to die from the disease compared to white patients. The disparity is attributed to younger age at diagnosis rather than genetic differences, according to Dr. Shella Saint Fleur-Lominy.
A new national study reveals a strong link between Agent Orange exposure and the risk of developing myelodysplastic syndrome, with exposed veterans diagnosed at younger ages and experiencing more aggressive disease. The study found that those with MDS were nearly twice as likely to see their disease progress within two years after diag...
The azacitidine-venetoclax combination significantly improves event-free survival and overall response rates compared to intensive chemotherapy. Patients in the aza-ven arm also experience lower symptom burdens, reduced depression, and improved quality of life.
Black patients with acute myeloid leukemia are diagnosed at younger ages and have worse outcomes compared to white patients, according to a study analyzing data from 10 clinical trials over 34 years. The study found that Black patients had a higher risk of dying from AML and any cause, even when treated with similar mutations.
Researchers found that measurable residual disease (MRD) is strongly associated with long-term outcomes in AML patients, providing a reliable indicator of treatment response. MRD testing may help refine how physicians assess treatment efficacy and personalize post-remission care.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
Researchers have identified a new histone variant, macroH2A1.1, as a potential therapeutic target for treating Acute Myeloid Leukaemia. The study found that targeting this variant is safe for patients and may lead to new treatment options.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
A new study reveals that combining proteasome inhibitors with Lys05 can effectively kill AML cells by disabling backup survival pathways. This approach has shown promise in preclinical models and could lead to improved treatment options for a wider range of AML patients.
A recent study published in Leukemia found that age-based classifications in acute myeloid leukemia (AML) treatment may be outdated. The research analyzed data from 2,823 adult AML patients, revealing nuanced age-related trends in genetic mutations and survival outcomes.
Researchers at City of Hope have identified a potential strategy to overcome treatment resistance in acute myeloid leukemia and uncovered racial disparities in triple-negative breast cancer. By targeting the ALKBH1 protein, which enhances energy production in cancer cells, scientists found that blocking this protein could make CAR T th...
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
Researchers have identified a previously unknown molecular mechanism behind chemoresistance in acute myeloid leukemia (AML), a type of blood cancer. The study found that a protein called RUNX1C plays a key role in this process, and blocking its activity with RNA-targeting tools can improve chemotherapy's effectiveness.
The study identified significant alterations in chromatin accessibility of cis-regulatory elements associated with AML differentiation, linked to mutations in the WT1 transcription factor gene. These changes led to reduced chromatin accessibility and downregulation of target genes, promoting AML proliferation.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Researchers found olutasidenib to be highly effective in patients with myelodysplastic syndrome (MDS) and IDH1 mutations. The study showed a response rate of 59% and improved blood count improvement, long duration of response, and overall survival rates. This breakthrough offers new treatment options for these patients.
A new study has found that TAF1 operates as a key molecular switch in adult hematopoietic stem cell maintenance and lineage commitment. This discovery challenges prevailing models of gene regulation and has the potential to lead to new therapeutic strategies targeting the molecule, which could improve blood production and transplantation.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
Researchers created a powerful cell culture model using induced pluripotent stem cells from a patient with MDS, confirming that the CEBPA mutation drives disease progression. The model could lead to new ways to treat and diagnose MDS and avoid more serious conditions.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
A new study reveals that SETD1B plays a critical role in supporting the growth of aggressive acute myeloid leukemia (AML) cells, particularly in those with FLT3-ITD mutations. By targeting SETD1B, researchers believe it may be possible to develop more effective treatments.
Researchers at St. Jude Children's Research Hospital have identified a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML) fueled by NUP98 fusions. Targeting the complex alone or in combination with another anticancer drug significantly increased survival in AML model systems.
Scientists discovered that taurine drives leukemia growth by promoting glycolysis and is produced by normal cells in the bone marrow microenvironment. Researchers identified taurine transporter expression as essential for leukemia cell growth, leading to potential new therapeutic targets.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
A new study published in Genes & Diseases journal introduces a novel therapeutic approach for acute myeloid leukemia (AML) using the METTL3 degrader ZW27941. The research team found that ZW27941 exhibited potent anti-leukemic activity and synergistic effects with existing AML therapies.
A study by UC San Francisco found that children with ALL living in mixed middle- and low-income neighborhoods have a 30-40% higher risk of death. In contrast, AML hospital treatments are shorter, and outpatient visits fewer, reducing challenges for underserved patients.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A new gene expression atlas from single-cell RNA sequencing data reveals normal hematopoietic cell differentiation patterns and identifies novel AML cell states. Researchers cataloged multiple ways aberrant differentiation leads to AML, with potential biomarkers and drug targets emerging.
A new CAR NK cell therapy has shown promising results in treating relapsed or refractory blood cancers, particularly AML. The therapy, SENTI-202, employs logic gating to improve specificity and reduce toxicity, and has been associated with complete remissions in seven of nine patients.